Zealand Pharma (ZEAL) investor relations material

Strategic priorities and pipeline development

• Focused on addressing the obesity pandemic and related diseases, leveraging over 25 years in peptide drug discovery and metabolic research.

• Key assets include Petrelintide (partnered with Roche) and Survodutide (partnered with Boehringer Ingelheim), with significant efforts and attention this year.

• Plans to expand the pipeline to over 10 clinical candidates in the next four years, supported by a new Boston research hub and increased partnerships.

• Strong financial position with $2.3 billion in cash and an expected $700 million more this year to support ambitions.

Clinical insights and product differentiation

• Petrelintide phase II data showed double-digit weight loss with a placebo-like GI tolerability profile; no patients experienced vomiting.

• Real-world evidence suggests current GLP-1 therapies provide 8–12% average weight loss, with high discontinuation rates due to GI side effects.

• Petrelintide aims to offer a simpler titration and better persistence, with minimal difference between efficacy and treatment estimands.

• Combination therapy with Petrelintide and CT-388 targets patients needing higher weight loss, with co-formulation confirmed as a key strategy.

Clinical trial design and future plans

• Phase III Petrelintide trial will optimize site selection and population mix, anticipating around 70% female enrollment for maximum efficacy.

• Phase III monotherapy trial for Petrelintide expected to start in the second half of the year, pending full data and regulatory meetings.

• Phase II study for the Petrelintide/CT-388 combination to begin soon, aiming to address both obesity and type 2 diabetes populations.

• Full phase III Survodutide program, including SYNCHRONIZE-1 and 2 and cardiovascular outcome studies, will report data this year.